Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: A case control study

Cancer Imaging

Volumn 16, Issue 1, 2016, Pages

  Lee, Ji Hyun ^a   Lee, Ho Yun ^a   Ahn, Myung Ju ^a   Park, Keunchil ^a   Ahn, Jin Seok ^a   Sun, Jong Mu ^a   Lee, Kyung Soo ^a  

^a Samsung Medical Center   (South Korea)

Author keywords

Biomarkers; Growth kinetics; Prognosis; Quantitative analysis; Tumor volume

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; MUTANT PROTEIN; ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CASE CONTROL STUDY; FEMALE; FOLLOW UP; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT ASSESSMENT; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TUMOR GROWTH; TUMOR VOLUME; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFECT; GENETICS; LUNG TUMOR; MIDDLE AGED; MUTATION; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROCEDURES; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; RETROSPECTIVE STUDY; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADENOCARCINOMA OF LUNG; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; CONTRAST MEDIA; DISEASE PROGRESSION; ERBB RECEPTORS; ERLOTINIB HYDROCHLORIDE; FEMALE; FOLLOW-UP STUDIES; GEFITINIB; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TOMOGRAPHY, SPIRAL COMPUTED; TUMOR BURDEN; YOUNG ADULT;

EID: 85007623437     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1186/s40644-016-0063-7     Document Type: Article

References (26)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55(1):10-30.
2. Takano T, Fukui T, Ohe Y, Tsuta K, Yamamoto S, Nokihara H, et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol. 2008;26(34):5589-95. doi:10.1200/JCO.2008.16.7254.
3. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-57. doi:10.1056/NEJMoa0810699.
4. Van Zandwijk N, Mathy A, Boerrigter L, Ruijter H, Tielen I, De Jong D, et al. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. Ann Oncol. 2007;18(1):99-103. doi:10.1093/annonc/mdl323.
5. Jaffe CC. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol. 2006;24(20):3245-51. doi:10.1200/JCO.2006.06.5599.
6. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet. 2000;356(9227):373-8.
7. Lee HY, Hyun SH, Lee KS, Kim BT, Kim J, Shim YM, et al. Volume-based parameter of 18) F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. Ann Surg Oncol. 2010;17(10):2787-94. doi:10.1245/s10434-010-1107-z.
8. Goldmacher GV, Conklin J. The use of tumour volumetrics to assess response to therapy in anti-cancer clinical trials. Br J Clin Pharmacol. 2012;73:846-54. doi:10.1111/j.1365-2125.2012.04179.x.
9. Mozley PD, Bendtsen C, Zhao B, Schwartz LH, Thorn M, Rong Y, et al. Measurement of tumor volumes improves RECIST-based response assessments in advanced lung cancer. Transl Oncol. 2012;5(1):19-25.
10. Mozley PD, Schwartz LH, Bendtsen C, Zhao B, Petrick N, Buckler AJ. Change in lung tumor volume as a biomarker of treatment response: a critical review of the evidence. Ann Oncol. 2010;21(9):1751-5. doi:10.1093/annonc/mdq051.
11. Nishino M, Guo M, Jackman DM, DiPiro PJ, Yap JT, Ho TK, et al. CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool. Acad Radiol. 2011;18(1):54-62. doi:10.1016/j.acra.2010.08.021.
12. Zhao B, Schwartz LH, Moskowitz CS, Ginsberg MS, Rizvi NA, Kris MG. Lung cancer: computerized quantification of tumor response-initial results. Radiology. 2006;241(3):892-8. doi:10.1148/radiol.2413051887.
13. Zhao B, Oxnard GR, Moskowitz CS, Kris MG, Pao W, Guo P, et al. A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clin Cancer Res. 2010;16(18):4647-53. doi:10. 1158/1078-0432. CCR-10-0125.
14. Schwartz LH, Curran S, Trocola R, Randazzo J, Ilson D, Kelsen D. Volumetric 3D CT analysis-an early predictor of response to therapy. J Clin Oncol. 2007;25 Suppl 18:4576.
15. Altorki N, Heymach J, Guarino M, Lee H, Felip E, Bauer TI. Phase II study of pazopanib (GW786034) given preoperatively in stage I-II non-small cell lung cancer (NSCLC): a proof-of-concept study. Ann Oncol. 2008;19 Suppl 8:124.
16. Kim ST, Uhm JE, Lee J, Sun JM, Sohn I, Kim SW, et al. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer. 2012;75(1):82-8. doi:10.1016/j.lungcan. 2011.05.022.
17. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125(7):605-13.
18. Grothey A, Hedrick EE, Mass RD, Sarkar S, Suzuki S, Ramanathan RK, et al. Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol. 2008;26(2):183-9. doi:10.1200/jco.2007.13.8099.
19. Kozak MM, Murphy JD, Schipper ML, Donington JS, Zhou L, Whyte RI, et al. Tumor volume as a potential imaging-based risk-stratification factor in trimodality therapy for locally advanced non-small cell lung cancer. J Thorac Oncol. 2011;6(5):920-6.
20. Prasad SR, Jhaveri KS, Saini S, Hahn PF, Halpern EF, Sumner JE. CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations. Radiology. 2002;225(2):416-9. doi:10.1148/radiol.2252011604.
21. Claret L, Gupta M, Han K, Joshi A, Sarapa N, He J, et al. Evaluation of Tumor-Size Response Metrics to Predict Overall Survival in Western and Chinese Patients With First-Line Metastatic Colorectal Cancer. J Clin Oncol. 2013;31:2110-4. doi:10.1200/jco.2012.45.0973.
22. Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, Lück HJ, et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol. 2008;26(12):1987-92.
23. Collette L, Burzykowski T, Carroll KJ, Newling D, Morris T, Schröder FH. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. J Clin Oncol. 2005;23(25):6139-48.
24. Sherrill B, Amonkar M, Wu Y, Hirst C, Stein S, Walker M, et al. Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer. Br J Cancer. 2008;99(10):1572-8.
25. Soria J, Massard C, Le Chevalier T. Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann Oncol. 2010;21(12):2324-32.
26. Maitland ML, Schwartz LH, Ratain MJ. Time to tumor growth: a model end point and new metric system for oncology clinical trials. J Clin Oncol. 2013;31:2070-2. doi:10.1200/jco.2013.49.3635.